Clinical trials: Behavioral Symptoms
Urinary Incontinence
This Study Will Collect Clinical and Patient Reported Satisfaction Data From Males Requiring Urine Output Management Overnight in the Home Setting.
This post-market study will assess the performance of and user satisfaction with the PureWick® Male External Catheter in a home setting.
- Trial name
- PUREST-M (NCT06850259)
- Testing
- PureWick® Urine Collection System, UltraFlex™ Self-Adhering Male External Catheter
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- C. R. Bard
Bullying, Cyberbullying
An Evidence-based Approach for Bullying Prevention
This Phase II SBIR project is designed to address the critical public health problem of bullying and cyberbullying among middle school age youth.
- Conditions
- Bullying, Cyberbullying, Substance Use, Substance Abuse
- Trial name
- NCT03205059
- Testing
- LST MS curriculum+ Bullying/Cyberbulling serious game, LST MS curriculum
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- National Health Promotion Associates, Inc.
Traumatic Brain Injury, Alexithymia
The Emotion Builder: An Intervention for Emotional Deficits After Brain Injury
The purpose of this study is to examine a web-based training program for treating emotional problems in people who have suffered a traumatic brain injury (TBI).
- Trial name
- NCT02432300
- Testing
- Emotion Builder
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- EmotEd
Treatment Resistant Depression, Major Depressive Disorder
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)
This study is a multi-center, open-label trial to evaluate the long-term safety and efficacy of AXS-05 in subjects with major depressive disorder with prior treatment failures
- Trial name
- NCT04634669
- Testing
- AXS-05 (dextromethorphan-bupropion)
- Where
- 20 sites in United States
- Volunteers
- 181 people
- Sponsor
- Axsome Therapeutics, Inc.
Depression
Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects
The purpose of this study is to determine the effect of a single dose infusion of AZD 6765 compared with placebo and ketamine on the blood oxygen level dependent signal using fMRI (functional Magnetic Resonance Imaging) in…
- Trial name
- NCT01046630
- Testing
- AZD6765, Ketamine
- Where
- 2 sites in United Kingdom
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Kidney Diseases
Secondary Data Analysis of Patients at Risk for CKD to Inspect CKD Prevalence, Diagnosis Rates, Diagnostic Behaviour, Treatment Patterns and Patient Characteristics
This study is a national secondary data analysis to determine the prevalence of diagnosed and undiagnosed CKD in German primary care offices in a patient population at high risk for the development and progression of CKD.
- Trial name
- InspeCKD (NCT05953701)
- Where
- Germany
- Volunteers
- 800,211 people
- Sponsor
- AstraZeneca
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
This a Phase 2a, multicenter, randomized, double-blind, placebo controlled 3 arm study to assess the safety and tolerability of multiple oral doses of REL-1017 25 mg and 50 mg as adjunctive therapy in the treatment of patients…
- Trial name
- NCT03051256
- Testing
- REL-1017
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- Relmada Therapeutics, Inc.
Lactose Intolerance
Effects Comparison of A1 and A2 Milk on Gastrointestinal Physiology, Symptoms and Cognitive Behavior
This is a single-site, double-blinded, randomized, controlled, 2X2 cross-over study aiming to compare effects of milk containing only A2 type beta casein versus milk containing both A1 and A2 beta casein proteins on the…
- Trial name
- NCT02406469
- Testing
- Oral consumption milk Tetra Pak
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- a2 Milk Company Ltd.
Major Depressive Disorder
Study of NSI-189 for Major Depressive Disorder
The study will consist of a screening period and a randomized treatment. Approximately 220 subjects who meet eligibility during the screening period will be randomized to initiate a 12-week, double-blind treatment with NSI-189 80…
- Trial name
- NCT02695472
- Testing
- 80 Milligrams NSI-189, 40 Milligrams NSI-189
- Where
- 13 sites in United States
- Volunteers
- 220 people
- Sponsor
- Neuralstem Inc.
Dehydration
Dehydration, Rehydration, and Blood Viscosity
The purpose of this study is to examine and compare the rehydration effect of Essentia Water, an electrolyzed high-pH bottled water, with industry-standard bottled water purified by reverse osmosis with minerals added, on (1)…
- Trial name
- NCT02118883
- Testing
- Essentia Water, Bottled water
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Essentia Water, LLC
Depressive Disorder
An Eight-Week Study Evaluating the Efficacy of Two Fixed Doses (250 mg Twice Daily and 100 mg Twice Daily) of SSR149415 in Patients With Major Depressive Disorder
The purpose of the study is to evaluate the efficacy of SSR149415 in the treatment of Major Depressive Disorder, defined as a change from baseline to visit 7 in the Hamilton Depression Rating Scale.
- Trial name
- LENA (NCT00361491)
- Testing
- SSR149415
- Where
- 7 sites in Argentina, Bulgaria and 5 more
- Volunteers
- 324 people
- Sponsor
- Sanofi
Bipolar Disorder
Study Evaluating Bifeprunox in Bipolar Depression
The purpose of the study is to investigate whether eight weeks of treatment with flexible doses of bifeprunox is superior to treatment with placebo in depressed patients with bipolar disorder.
- Trial name
- NCT00134459
- Testing
- Bifeprunox
- Where
- 40 sites in United States
- Volunteers
- 434 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to determine the long-term efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.
- Trial name
- NCT00707980
- Testing
- Vortioxetine
- Where
- 92 sites in United States, Australia and 15 more
- Volunteers
- 836 people
- Sponsor
- Takeda
Major Depressive Disorder
Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine
The purpose of the study is to describe the association/correlation between change in patient-reported cognitive symptoms and work productivity in gainfully employed patients receiving vortioxetine for a Major Depressive Episode…
- Trial name
- AtWoRC (NCT02332954)
- Testing
- vortioxetine
- Where
- 26 sites in Canada
- Volunteers
- 226 people
- Sponsor
- Lundbeck Canada Inc.
Mental Fatigue, Mental Stress
tAN for First Responders
This study is designed as an open label, single arm, decentralized clinical study in which first responders will receive transcutaneous auricular neurostimulation (tAN), which targets the auricular branch of the vagus nerve…
- Trial name
- NCT07109349
- Testing
- Sparrow Link
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Spark Biomedical, Inc.
Mental Competency, Mental Fatigue
Pharmaton Upgrade in Improving Mental Performance and Decreasing Fatigue
To assess the efficacy and safety of Pharmaton? PHL 00749 in improving cognitive function and allevi ating mental and physical stress in healthy male and female subjects leading demanding lifestyles.
- Trial name
- NCT00144235
- Testing
- Pharmaton PHL 00749
- Where
- United Kingdom
- Volunteers
- 412 people
- Sponsor
- Boehringer Ingelheim
Obesity
BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management
The purpose of this study is to assess the weight loss effect of lorcaserin at the end of the first year of treatment (Week 52) and to assess the ability of lorcaserin to maintain weight loss at the end of the second year of…
- Trial name
- NCT00395135
- Testing
- Lorcaserin 10 mg BID
- Where
- United States
- Volunteers
- 3,182 people
- Sponsor
- Eisai Inc.
Major Depressive Disorder
Major Depressive Disorder With Mixed Features
Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features.
- Trial name
- RESOLVE2 (NCT01423240)
- Testing
- Lurasidone 20 mg, Lurasidone 60 mg
- Where
- 27 sites in United States
- Sponsor
- Sumitomo Pharma America, Inc.
Patient Activation
Induced Physiological Ketosis in Asthenia and\or Decreased Tolerance to Physical and\or Mental Exertion
The purpose of this study is evaluating of efficacy of innovative dietary strategy -stimulation of physiological ketosis with Liquid Technology Formula PanTrek, in patients with asthenia and or decreased tolerance to physical…
- Trial name
- NCT05689697
- Testing
- PanTrek
- Where
- Russia
- Volunteers
- 88 people
- Sponsor
- Ketonic Pharm LLC
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Sexual Functioning Study With Antidepressants
Effects of two depression medication on sexual functioning
- Trial name
- NCT00316160
- Testing
- Bupropion Hydrochloride Extended-release, Extended-release Venlafaxine
- Where
- 45 sites in United States
- Volunteers
- 347 people
- Sponsor
- GlaxoSmithKline